Cargando…

Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study

OBJECTIVE: Primary platinum-resistant epithelial ovarian cancer (EOC) is an area of unmet medical need. There is limited evidence from small studies that platinum-based combinations can overcome “resistance” in a proportion of patients. We investigated the efficacy and toxicity of platinum-based com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sayal, Karen, Gounaris, Ioannis, Basu, Bristi, Freeman, Sue, Moyle, Penny, Hosking, Karen, Iddawela, Mahesh, Jimenez-Linan, Mercedes, Abraham, Jean, Brenton, James, Hatcher, Helen, Earl, Helena, Parkinson, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Ovarian Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485738/ https://www.ncbi.nlm.nih.gov/pubmed/25962114 http://dx.doi.org/10.1097/IGC.0000000000000448

Ejemplares similares

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study
por: Parkinson, Christine A., et al.
Publicado: (2016)

Genetics Consultation Rates Following a Diagnosis of High-Grade Serous Ovarian Carcinoma in the Canadian Province of Ontario
por: McGee, Jacob, et al.
Publicado: (2017)

High co‐expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer
por: Wu, Xiaodong, et al.
Publicado: (2022)

High Pretreatment Plasma D-dimer Levels Are Associated With Poor Prognosis in Patients With Ovarian Cancer Independently of Venous Thromboembolism and Tumor Extension
por: Sakurai, Manabu, et al.
Publicado: (2015)

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers
por: Sölétormos, György, et al.
Publicado: (2016)

Risk of Ovarian Cancer Relapse Score: A Prognostic Algorithm to Predict Relapse Following Treatment for Advanced Ovarian Cancer
por: Rizzuto, Ivana, et al.
Publicado: (2015)

Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials
por: Friedlander, Michael L., et al.
Publicado: (2016)

Differences in Clinical and Biological Features Between Type I and Type II Tumors in FIGO Stages I-II Epithelial Ovarian Carcinoma
por: Skirnisdottir, Ingiridur, et al.
Publicado: (2015)

Pure Immature Teratoma of the Ovary in Adults: Thirty-Year Experience of a Single Tertiary Care Center
por: Alwazzan, Ahmad Bakr, et al.
Publicado: (2015)

Understanding Lymphatic Drainage Pathways of the Ovaries to Predict Sites for Sentinel Nodes in Ovarian Cancer
por: Kleppe, Marjolein, et al.
Publicado: (2015)

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study
por: Oza, Amit M., et al.
Publicado: (2017)

Expression of Tissue Factor in Epithelial Ovarian Carcinoma Is Involved in the Development of Venous Thromboembolism
por: Sakurai, Manabu, et al.
Publicado: (2017)

Applying Precision Medicine to Ovarian Cancer: Proof-of-Principle for a “Molecular Second Look”
por: Schwartz, Melissa, et al.
Publicado: (2018)

Cellular Senescence in the Treatment of Ovarian Cancer
por: Wang, Zehua, et al.
Publicado: (2018)

Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Wang, Haihong, et al.
Publicado: (2018)

Short-term Outcomes and Pregnancy Rate After Laparoscopic Fertility-Sparing Surgery for Borderline Ovarian Tumors: A Single-Institute Experience
por: Zhao, Jianguo, et al.
Publicado: (2018)

Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study
por: Maritschnegg, Elisabeth, et al.
Publicado: (2018)

The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer
por: Zhu, Xinxin, et al.
Publicado: (2018)

Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future
por: Colombo, Nicoletta, et al.
Publicado: (2017)

Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer
por: Krell, Daniel, et al.
Publicado: (2017)

Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer—A National Cancer Database Study
por: Leiserowitz, Gary S., et al.
Publicado: (2017)

Modulation of non-coding RNAs by resveratrol in ovarian cancer cells: In silico analysis and literature review of the anti-cancer pathways involved
por: Vallino, Letizia, et al.
Publicado: (2020)

Differential effects of thymoquinone on lysophosphatidic acid-induced oncogenic pathways in ovarian cancer cells
por: Ha, Ji Hee, et al.
Publicado: (2020)

Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy
por: Zhao, Chong, et al.
Publicado: (2016)

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
por: Rao, S, et al.
Publicado: (2008)

Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma
por: Wen, Feng, et al.
Publicado: (2016)

A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma
por: Starling, N, et al.
Publicado: (2009)

Long-term platinum retention after treatment with cisplatin and oxaliplatin
por: Brouwers, Elke EM, et al.
Publicado: (2008)

Cisplatin-Membrane Interactions and Their Influence on Platinum Complexes Activity and Toxicity
por: Martinho, Nuno, et al.
Publicado: (2019)

Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug Sensitivity
por: Möltgen, Sophie, et al.
Publicado: (2020)

Platinum
Publicado: (1860)

Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer
por: Takekuma, Munetaka, et al.
Publicado: (2015)

New ways of assessing ovarian cancer response: metabolic imaging and beyond
por: Rockall, Andrea, et al.
Publicado: (2012)

Recent advances in systemic treatments for ovarian cancer
por: Banerjee, Susana, et al.
Publicado: (2012)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

Identification of Cisplatin-Binding Proteins Using Agarose Conjugates of Platinum Compounds
por: Karasawa, Takatoshi, et al.
Publicado: (2013)

Phenethylisothiocyanate Potentiates Platinum Therapy by Reversing Cisplatin Resistance in Cervical Cancer
por: Mahapatra, Elizabeth, et al.
Publicado: (2022)

Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis
por: Ostwal, Vikas, et al.
Publicado: (2017)

Erratum: Thermal Expansion of Platinum and Platinum-Rhodium Alloys
por: Edsinger, RE, et al.
Publicado: (2014)

Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial
por: Alderson, Derek, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9nhuhi5364shfjia0v9f2hjrg5